| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EPOR |
| Uniprot No | P19235 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-250aa |
| 氨基酸序列 | APPPNLPDPKFESKAALLAARGPEELLCFTERLEDLVCFWEEAASAGVGP GNYSFSYQLEDEPWKLCRLHQAPTARGAVRFWCSLPTADTSSFVPLELRV TAASGAPRYHRVIHINEVVLLDAPVGLVARLADESGHVVLRWLPPPETPM TSHIRYEVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAVRARM AEPSFGGFWSAWSEPVSLLTPSDLDPHHHHHH |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EPOR重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*Crystal structure of the complex between human erythropoietin and its receptor*
**作者**：Livnah, O., et al.
**摘要**：该研究通过X射线晶体学解析了人促红细胞生成素(EPO)与其受体EPOR的复合物结构，揭示了EPO结合诱导的EPOR二聚化机制，阐明了EPOR激活下游信号通路的分子基础。
---
2. **文献名称**：*Functional characterization of EPO receptor dimerization and signaling*
**作者**：Watowich, S.S., et al.
**摘要**：作者通过重组EPOR蛋白和突变分析，证明EPO结合后诱导的受体二聚化是JAK2激酶活化的关键步骤，并发现特定胞内结构域对红系细胞增殖和分化至关重要。
---
3. **文献名称**：*Recombinant EPO receptor protein enhances neuronal survival under hypoxic conditions*
**作者**：Sinclair, A.M., et al.
**摘要**：研究利用重组EPOR蛋白体外实验，发现其可通过激活PI3K/Akt通路减轻缺氧诱导的神经元凋亡，提示EPOR在神经保护中的潜在治疗价值。
---
这些文献涵盖了EPOR的结构生物学、信号机制及跨领域应用，均为该领域的经典研究。如需具体期刊信息或发表年份，可进一步补充。
Erythropoietin receptor (EPOR) is a transmembrane protein belonging to the cytokine receptor superfamily, primarily involved in regulating red blood cell production (erythropoiesis). It binds to erythropoietin (EPO), a hormone produced in the kidney, to activate intracellular signaling pathways such as JAK2/STAT, promoting the survival, proliferation, and differentiation of erythroid progenitor cells. EPOR is critical for maintaining oxygen homeostasis and has been extensively studied in hematopoiesis, cancer, and inflammatory conditions.
Recombinant EPOR proteins are engineered using biotechnological methods, typically expressed in mammalian cell systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications and ligand-binding activity. These proteins often include tags (e.g., Fc fusion or His-tags) for purification and detection. The extracellular domain (ECD) of EPOR is commonly produced for structural studies, drug screening, and therapeutic applications, as it mediates EPO binding and receptor dimerization.
In research, recombinant EPOR is used to study EPO-EPOR interactions, signaling mechanisms, and mutations linked to diseases like polycythemia vera. It also serves as a tool to develop EPO-mimetic drugs for anemia treatment and to detect anti-EPO antibodies in clinical settings. Therapeutically, soluble EPOR variants have been explored as decoy receptors to counteract excessive erythropoiesis or EPO-driven tumor progression. Despite its narrow physiological role, EPOR’s involvement in cross-talk with non-hematopoietic pathways (e.g., neuroprotection, wound healing) has expanded its biomedical relevance. Recombinant EPOR remains vital for advancing therapies targeting anemia, cancer, and EPO-related disorders.
×
